A New Paradigm in Oxygen Delivery
NuvOx’s discovery of NanO as the world’s most effective oxygen therapeutic derives from Dr. Unger’s pioneering work in microbubbles. Dr. Unger’s first company, ImaRx Pharmaceutical, developed the world’s #1 selling microbubble product, Definity®, as an ultrasound contrast agent.
The active substance in microbubbles is a class of compounds called perfluorocarbons. Several generations of perfluorocarbon emulsions were developed as blood substitutes. The early generations used perfluorocarbons with high boiling points (greater than 142 C). Dr. Unger recognized that perfluorocarbons with lower boiling points, as used in microbubbles, would be more efficient oxygen carriers.
Dodecafluoropentane emulsion (DDFPe) was originally developed as an ultrasound contrast agent that never launched. Dodecafluoropentane boils at 29 C, less than body temperature, but is stable to storage as a liquid nanoemulsion. Recognizing the potential of DDFPe to deliver far more oxygen than previous perfluorocarbons, Dr. Unger licensed the patents and obtained ownership of the regulatory documents for DDFPe and launched the program to develop NanO .
NanO improves the flow of oxygen between blood and tissue. Multiple studies have confirmed the potential of NanO showing efficacy at less than 1% the dose of the prior perfluorocarbons. NanO represents a new paradigm in oxygen delivery.
NanO 's unique mechanism of action allows it to improve the flow of oxygen from lungs to blood and from blood to tissue. Over 30 animal studies have shown therapeutic effect in seven different indications where hypoxia is life threatening.
Sickle Cell Crisis
AHRF / COVID-19
The road ahead.
During the COVID-19 pandemic, the company's focus is on initiating a clinical trial in COVID-19 patients with Acute Hypoxemic Respiratory Failure (AHRF). COVID-19 kills via hypoxia - and NuvOx has a drug to treat hypoxia.
NanO has completed Phase Ib/II clinical trials in acute ischemic stroke and glioblastoma (see publications section), and plans to resume trials in these indications when it is possible to enroll patients again.